Sobi, a Swedish pharmaceutical company, specializes in rare diseases within hematology and immunology. With a medium risk ESG score of 21.3, Sobi has a strong background in recombinant proteins such as hemophilia factors. Through strategic partnerships and acquisitions, Sobi has expanded its product portfolio to include treatments for various rare diseases. Notably, Sobi has launched innovative hemophilia products and continues to develop its immunology and hematology pipeline.